Activation of the contact system and fibrinolysis in autoimmune acquired angioedema

A rationale for prophylactic use of tranexamic acid

Massimo Cugno, Marco Cicardi, Angelo Agostoni

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Cl-inhibitor deficiency results in bouts of mucocutaneous edema and may be inherited (hereditary angioedema) or acquired (acquired angioedema [AAE]). The two forms have the same clinical picture but differ in the response to treatment. Prophylaxis with antifibrinolytic agents produces better results in the acquired form than in the inherited form, in which androgen derivatives are more effective. It is hypothesized that activation of the contact and fibrinolytic systems is involved in the pathogenesis of attacks. We evaluated these two systems in plasma from eight patients with AAE and anti-Cl-inhibitor autoantibodies (autoimmune AAE) by measuring the cleavage of high molecular weight kininogen and the complexes formed by plasmin and its inhibitor α2-antiplasmin. We also measured complement parameters, autoantibody titer, and cleaved Cl-inhibitor (relative molecular mass = 96,000), because autoantibodies to Cl-inhibitor are known to facilitate its cleavage by proteases. Plasma was obtained from patients in remission, during prophylactic treatment with the antifibrinolytic agent tranexamic acid (2 to 4.5 gm/day) and also from two patients during acute attacks of edema. Levels of cleaved high molecular weight kininogen and antiplasmin-plasmin complexes in patients with AAE were both higher in basal conditions, during treatment, and during acute attacks than those in normal subjects (p <0.001). The cleaved inactive form of Cl-inhibitor was also present in all patients in all three conditions. Therapy with antifibrinolytic agents reduced the frequency and intensity of symptoms without significantly changing any of the biochemical parameters. Our data demonstrate that in patients with autoimmune AAE there is continuous activation of contact and fibrinolytic systems, which might be counteracted by antifibrinolytic agents, as indicated by the favorable effects of prophylactic treatment with tranexamic acid.

Original languageEnglish
Pages (from-to)870-876
Number of pages7
JournalJournal of Allergy and Clinical Immunology
Volume93
Issue number5
DOIs
Publication statusPublished - 1994

Fingerprint

Tranexamic Acid
Antifibrinolytic Agents
Fibrinolysis
High Molecular Weight Kininogens
Autoantibodies
Edema
Hereditary Angioedemas
Therapeutics
Fibrinolysin
Acquired angioedema
Androgens
Peptide Hydrolases

Keywords

  • Acquired angioedema
  • autoimmunity
  • Cl-inhibitor
  • high molecular weight kininogen
  • plasmin
  • tranexamic acid

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Activation of the contact system and fibrinolysis in autoimmune acquired angioedema : A rationale for prophylactic use of tranexamic acid. / Cugno, Massimo; Cicardi, Marco; Agostoni, Angelo.

In: Journal of Allergy and Clinical Immunology, Vol. 93, No. 5, 1994, p. 870-876.

Research output: Contribution to journalArticle

@article{6802935910ff4c8d8633aad5dafd7527,
title = "Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: A rationale for prophylactic use of tranexamic acid",
abstract = "Cl-inhibitor deficiency results in bouts of mucocutaneous edema and may be inherited (hereditary angioedema) or acquired (acquired angioedema [AAE]). The two forms have the same clinical picture but differ in the response to treatment. Prophylaxis with antifibrinolytic agents produces better results in the acquired form than in the inherited form, in which androgen derivatives are more effective. It is hypothesized that activation of the contact and fibrinolytic systems is involved in the pathogenesis of attacks. We evaluated these two systems in plasma from eight patients with AAE and anti-Cl-inhibitor autoantibodies (autoimmune AAE) by measuring the cleavage of high molecular weight kininogen and the complexes formed by plasmin and its inhibitor α2-antiplasmin. We also measured complement parameters, autoantibody titer, and cleaved Cl-inhibitor (relative molecular mass = 96,000), because autoantibodies to Cl-inhibitor are known to facilitate its cleavage by proteases. Plasma was obtained from patients in remission, during prophylactic treatment with the antifibrinolytic agent tranexamic acid (2 to 4.5 gm/day) and also from two patients during acute attacks of edema. Levels of cleaved high molecular weight kininogen and antiplasmin-plasmin complexes in patients with AAE were both higher in basal conditions, during treatment, and during acute attacks than those in normal subjects (p <0.001). The cleaved inactive form of Cl-inhibitor was also present in all patients in all three conditions. Therapy with antifibrinolytic agents reduced the frequency and intensity of symptoms without significantly changing any of the biochemical parameters. Our data demonstrate that in patients with autoimmune AAE there is continuous activation of contact and fibrinolytic systems, which might be counteracted by antifibrinolytic agents, as indicated by the favorable effects of prophylactic treatment with tranexamic acid.",
keywords = "Acquired angioedema, autoimmunity, Cl-inhibitor, high molecular weight kininogen, plasmin, tranexamic acid",
author = "Massimo Cugno and Marco Cicardi and Angelo Agostoni",
year = "1994",
doi = "10.1016/0091-6749(94)90380-8",
language = "English",
volume = "93",
pages = "870--876",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Activation of the contact system and fibrinolysis in autoimmune acquired angioedema

T2 - A rationale for prophylactic use of tranexamic acid

AU - Cugno, Massimo

AU - Cicardi, Marco

AU - Agostoni, Angelo

PY - 1994

Y1 - 1994

N2 - Cl-inhibitor deficiency results in bouts of mucocutaneous edema and may be inherited (hereditary angioedema) or acquired (acquired angioedema [AAE]). The two forms have the same clinical picture but differ in the response to treatment. Prophylaxis with antifibrinolytic agents produces better results in the acquired form than in the inherited form, in which androgen derivatives are more effective. It is hypothesized that activation of the contact and fibrinolytic systems is involved in the pathogenesis of attacks. We evaluated these two systems in plasma from eight patients with AAE and anti-Cl-inhibitor autoantibodies (autoimmune AAE) by measuring the cleavage of high molecular weight kininogen and the complexes formed by plasmin and its inhibitor α2-antiplasmin. We also measured complement parameters, autoantibody titer, and cleaved Cl-inhibitor (relative molecular mass = 96,000), because autoantibodies to Cl-inhibitor are known to facilitate its cleavage by proteases. Plasma was obtained from patients in remission, during prophylactic treatment with the antifibrinolytic agent tranexamic acid (2 to 4.5 gm/day) and also from two patients during acute attacks of edema. Levels of cleaved high molecular weight kininogen and antiplasmin-plasmin complexes in patients with AAE were both higher in basal conditions, during treatment, and during acute attacks than those in normal subjects (p <0.001). The cleaved inactive form of Cl-inhibitor was also present in all patients in all three conditions. Therapy with antifibrinolytic agents reduced the frequency and intensity of symptoms without significantly changing any of the biochemical parameters. Our data demonstrate that in patients with autoimmune AAE there is continuous activation of contact and fibrinolytic systems, which might be counteracted by antifibrinolytic agents, as indicated by the favorable effects of prophylactic treatment with tranexamic acid.

AB - Cl-inhibitor deficiency results in bouts of mucocutaneous edema and may be inherited (hereditary angioedema) or acquired (acquired angioedema [AAE]). The two forms have the same clinical picture but differ in the response to treatment. Prophylaxis with antifibrinolytic agents produces better results in the acquired form than in the inherited form, in which androgen derivatives are more effective. It is hypothesized that activation of the contact and fibrinolytic systems is involved in the pathogenesis of attacks. We evaluated these two systems in plasma from eight patients with AAE and anti-Cl-inhibitor autoantibodies (autoimmune AAE) by measuring the cleavage of high molecular weight kininogen and the complexes formed by plasmin and its inhibitor α2-antiplasmin. We also measured complement parameters, autoantibody titer, and cleaved Cl-inhibitor (relative molecular mass = 96,000), because autoantibodies to Cl-inhibitor are known to facilitate its cleavage by proteases. Plasma was obtained from patients in remission, during prophylactic treatment with the antifibrinolytic agent tranexamic acid (2 to 4.5 gm/day) and also from two patients during acute attacks of edema. Levels of cleaved high molecular weight kininogen and antiplasmin-plasmin complexes in patients with AAE were both higher in basal conditions, during treatment, and during acute attacks than those in normal subjects (p <0.001). The cleaved inactive form of Cl-inhibitor was also present in all patients in all three conditions. Therapy with antifibrinolytic agents reduced the frequency and intensity of symptoms without significantly changing any of the biochemical parameters. Our data demonstrate that in patients with autoimmune AAE there is continuous activation of contact and fibrinolytic systems, which might be counteracted by antifibrinolytic agents, as indicated by the favorable effects of prophylactic treatment with tranexamic acid.

KW - Acquired angioedema

KW - autoimmunity

KW - Cl-inhibitor

KW - high molecular weight kininogen

KW - plasmin

KW - tranexamic acid

UR - http://www.scopus.com/inward/record.url?scp=0028360198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028360198&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(94)90380-8

DO - 10.1016/0091-6749(94)90380-8

M3 - Article

VL - 93

SP - 870

EP - 876

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5

ER -